Immunotherapy plus standard chemotherapy for a genetic subtype of lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial combines an immunotherapy drug (a PD-1 inhibitor) with a standard chemotherapy regimen (R-CHOP) as the first treatment for a specific type of lymphoma that has a P53 mutation and PD-L1 expression. The goal is to see if this combination works better than standard treatment alone, potentially improving outcomes for patients with this genetic profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL).
- You have not yet received treatment for this cancer (this is your first treatment).
- Your cancer has a specific gene change called a P53 mutation and shows a protein called PD-L1.
- You are generally in good health, able to do light activities, and your blood and organ function tests are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.